Fierce Health Technology September 27, 2021
CVS Caremark is expanding its health equity efforts, setting goals that specifically target diseases that disproportionately impact patients of color, such as HIV and sickle cell disease.
For example, the pharmacy benefit management giant announced earlier this month that it aims to double the number of sickle cell patients on hydroxyurea, a low-cost medication that can help manage the condition by reversing changes to blood cells.
In tandem, CVS said it wants to improve adherence among people already taking hydroxyurea and significantly increase trait testing to identify people at risk more quickly.
Lucille Accetta, senior vice president for PBM and specialty product development at CVS Health, said the company is laser-focused on its initial goals to avoid biting off more...
Today's Sponsors
Today's Sponsor